Sarepta Therapeutics Stock Tumbles 42% Following Second Drug‑Linked Death Report
Shares of Sarepta Therapeutics Stock tumbled 42% after the biotech company reported a second death connected to its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. The news rattled investors, erasing market value and dragging the stock to nine-year lows.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
